MP-1 detects early retinal sensitivity loss in diabetics

Article

The microperimeter (MP-1) is ideal for detecting early retinal sensitivity loss in diabetic patients.

The microperimeter (MP-1) is ideal for detecting early retinal sensitivity loss in diabetic patients, claims a recent investigation in Retina.

Dr M.G. Nittala et al., Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India, completed several ophthalmic examinations on 210 eyes of 160 patients. This included best-corrected visual acuity, slit-lamp examination, indirect ophthalmoscopy and microperimetry. Subjects included healthy participants, diabetics with no retinopathy and patients suffering from different stages of diabetic retinopathy (DR).

Retinal sensitivity significantly decreased in correlation to DR severity. Mean foveal sensitivity was 16.68 ± 2.13 dB in healthy participants, 14.73 ± 3.64 dB in diabetics but no DR and 11.60 ± 5.76 dB in DR patients.

Diabetic patients with no DR experienced a significant loss of retinal sensitivity, compared to healthy subjects. Severe non-proliferative DR presented with a more significant loss of retinal sensitivity in he central 20, compared to those with other stages of DR.

The MP-1 is able to detect retinal sensitivity loss at an earlier stage in diabetic patients without DR. It is also a useful tool for measuring retinal sensitivity in DR patients. The MP-1 features scotomoa mapping, enabling the detection of functional vision in DR patients.

The abstract can be seen here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.